公开(公告)号：US20230212231A1

公开(公告)日：2023-07-06

申请号：US17927804

申请日：2021-05-26

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Baylor Research Institute ,  Assistance Publique - Hopitaux de Paris (APHP) ,  Universite Paris Est Creteil Val de Marne

Inventor： Yves LEVY ,  Gérard ZURAWSKI ,  Sandra ZURAWSKI ,  Christine LACABARATZ ,  Sylvain CARDINAUD ,  Mathieu SURENAUD

IPC: C07K14/005 ,  C07K16/28 ,  A61P31/14

CPC classification number: C07K14/005 ,  C07K16/2878 ,  C07K16/2851 ,  A61P31/14 ,  C12N2770/20022 ,  C07K2319/74 ,  C12N2770/20034 ,  A61K39/00

Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.

公开(公告)号：US20210299224A1

公开(公告)日：2021-09-30

申请号：US17301123

申请日：2021-03-25

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Hyemee JOO ,  Gerard ZURAWSKI

IPC: A61K38/20 ,  C07K14/54 ,  A61K39/00 ,  C07K16/28

Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

公开(公告)号：US20160331825A1

公开(公告)日：2016-11-17

申请号：US15111357

申请日：2015-01-13

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/395 ,  C12N7/00 ,  C07K16/28 ,  C07K14/005

CPC classification number: A61K39/12 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/585 ,  A61K2039/6056 ,  A61K2039/70 ,  C07K14/005 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2319/74 ,  C07K2319/91 ,  C12N7/00 ,  C12N2710/20034

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

Abstract translation: 实施例涉及针对人乳头状瘤病毒（HPV）和HPV相关疾病（包括多种类型的癌症）的新型疫苗。 HPV疫苗由抗人树突状细胞（DC）表面受体抗体，包括HPV16和18的CD40和E6 / 7蛋白组成。所述技术不限于制备针对HPV16和HPV18相关疾病的疫苗， 可用于从任何类型的HPV中制备携带E6 / 7的疫苗。 描述的HPV疫苗可以靶向DCs，主要和专业抗原呈递细胞（APC），并且可以诱导和激活有效的HPV E6 / 7特异性和强的CD4 +和CD8 + T细胞应答。 HPV疫苗可用于预防HPV感染和HPV相关疾病以及用于治疗HPV相关疾病，包括癌症。

公开(公告)号：US20240033340A1

公开(公告)日：2024-02-01

申请号：US18329696

申请日：2023-06-06

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/395 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/395 ,  A61K39/39541 ,  C07K16/2878 ,  A61K39/3955 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/20034 ,  A61K2039/505

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20230183366A1

公开(公告)日：2023-06-15

申请号：US17998611

申请日：2021-05-11

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCH MÉDICALE) ,  UNIVERSITE PARIS EST CRETEIL VAL DE MARNE ,  BAYLOR RESEARCH INSTITUTE ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： Yves LEVY ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K2317/565

Abstract: The disclosure relates to the field of OX40 activating proteins. More specifically, it is disclosed herein recombinant proteins with OX40 agonist antibodies or their antigen-binding fragments fused or linked to OX40 ligand. Also disclosed is the advantageous use of such OX40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens, and/or for treating cancer.

公开(公告)号：US20220175920A1

公开(公告)日：2022-06-09

申请号：US17598582

申请日：2020-03-26

Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université Paris est Cretéil Val de Marne ,  Baylor Research Institute ,  Assistance Publique-Hôpitaux de Paris (APHP)

Inventor： Yves LEVY ,  Valentina CEGLIA ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/395 ,  A61K39/385 ,  C07K14/705 ,  C07K16/28 ,  A61P31/18

Abstract: The disclosure relates to the field of CD40 activating proteins. More specifically, it is disclosed herein recombinant proteins with CD40 agonist antibodies or their antigen-binding fragments fused or linked to CD40 ligand. Also disclosed is the advantageous use of such CD40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens.

公开(公告)号：US20240131138A1

公开(公告)日：2024-04-25

申请号：US18269113

申请日：2021-12-22

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Assistance Publique - Hopitaux de Paris ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne

Inventor： Yves LEVY ,  Sylvain CARDINAUD ,  Mireille CENTLIVRE ,  Lydie DIEUDONNE ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI

IPC: A61K39/118 ,  A61P31/04 ,  C07K14/295 ,  C07K16/28

CPC classification number: A61K39/118 ,  A61P31/04 ,  C07K14/295 ,  C07K16/2851 ,  C07K16/2878 ,  A61K2039/505

Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.

公开(公告)号：US20240124532A1

公开(公告)日：2024-04-18

申请号：US18274848

申请日：2022-01-28

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Assistance Publique - Hopitaux de Paris ,  Universite Paris Est Creteil Val De Marne ,  Baylor Research Institute

Inventor： Yves LEVY ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI ,  Mireille CENTLIVRE ,  Lydie DIEUDONNE ,  Sylvain CARDINAUD

IPC: C07K14/295 ,  A61K39/118 ,  C07K16/28

CPC classification number: C07K14/295 ,  A61K39/118 ,  C07K16/2878 ,  C07K2319/33 ,  C07K2319/40

Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.

公开(公告)号：US20240010739A1

公开(公告)日：2024-01-11

申请号：US18036237

申请日：2021-11-10

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Assistance Publique - Hopitaux de Paris (APHP) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne

Inventor： Yves LEVY ,  Gérard ZURAWSKI ,  Mireille CENTLIVRE ,  Sandra ZURAWSKI ,  Véronique GODOT

IPC: C07K16/28 ,  C12N15/63

CPC classification number: C07K16/2875 ,  C07K16/2851 ,  C12N15/63 ,  C07K2317/24 ,  C07K2317/565 ,  A61K2039/505

Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells. The present invention thus relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the receptor-binding domain of the Sars-Cov-2 spike protein

公开(公告)号：US20190314481A1

公开(公告)日：2019-10-17

申请号：US16397214

申请日：2019-04-29

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  C07K14/005 ,  A61K39/395 ,  C07K16/28 ,  C12N7/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.